ArticleAnnals of surgical oncology2021
Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma.
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Exosomal microRNA-4800-3p in portal vein blood promotes liver metastasis in pancreatic cancer by targeting PLAA.Scientific reports · 2026Article
- Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer.NPJ precision oncology · 2025Article
- Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Surgical techniques and tumor dissemination: a critical review of the CETUPANC trial on the superior mesenteric arteryHepatobiliary surgery and nutrition · 2025Article
- Circulating tumor cells in pancreatic cancer: The prognostic impact in surgical patients.World journal of clinical oncology · 2024Article
- Circulating tumor cells as prognostic marker in pancreatic cancer.World journal of clinical oncology · 2024Article
- Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery.NPJ precision oncology · 2024Article
- Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis.Frontiers in oncology · 2024Article
- Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis.World journal of clinical oncology · 2023Article
- Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.Bioengineered · 2022Article
- Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.International journal of molecular sciences · 2022Review
- The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer.Frontiers in oncology · 2022Review
- Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications.Frontiers in cell and developmental biology · 2022Review
- Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients.Cancers · 2021Article
- Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer.Cancer management and research · 2021Article
- Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2021Article
- Epithelial-Mesenchymal Transition and Its Regulation Mechanisms in Pancreatic Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThis study investigated the safety and feasibility of intraoperative portal vein blood (PVB) collection at the time of pancreatic ductal adenocarcinoma (PDAC) resection. Relationships of circulating tumor cells (CTCs) in PVB and peripheral blood (PB) with overall survival (OS) and recurrence-free survival were studied.
methodsPatients undergoing PDAC resection were offered enrollment in a prospective liquid biopsy protocol. The patients had PB drawn before incision and PVB drawn before tumor mobilization, then again immediately after resection. Using standard CellSearch protocols, CTCs were identified and compared with OS.
resultsOf the 34 patients enrolled in this study, 23 (68%) underwent pancreaticoduodenectomy, 8 (23%) underwent distal pancreatectomy, and 3 (9%) underwent total pancreatectomy. Peripheral blood was available for 22 (65%) and PVB for 31 (91%) of the patients. No bleeding or thrombotic complications occurred with the PVB draws. The CTC counts per 7.5 mL of PVB collected before and after resection were highly correlated (R
conclusionsCollection of PVB during PDAC resection is safe. In this pilot study, PVB CTC counts but not PB CTC counts were significantly correlated with OS. This opens the door for future studies on selective omission of adjuvant chemotherapy for patients treated preoperatively and tailored surveillance intensity for patients without PVB CTCs at PDAC resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.